IPF Ofev denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Apply Step-Therapy Requirements to Ofev (nintedanib) for IPF

Cigna's step-therapy (also called "fail-first") protocols require that a patient try one or more preferred or lower-cost medications before the plan will approve a more expensive agent. For IPF, step-therapy creates a particular challenge because the FDA-approved antifibrotic options are limited, and there is no generic or lower-cost equivalent with the same mechanism and indication. A step-therapy denial for Ofev typically means Cigna wants documentation that another formulary-preferred agent was trialed first — or a clinical justification for why that trial is medically contraindicated or otherwise inappropriate for this specific patient.

## Why This Denial Is Appealable

Step-therapy overrides are explicitly recognized by most state insurance laws and by Cigna's own policies when the required first-step drug is (a) medically contraindicated, (b) previously trialed and failed or caused adverse effects, (c) otherwise clinically inappropriate per the prescriber's judgment, or (d) inconsistent with applicable guideline recommendations for this patient's clinical profile. Because IPF has a narrow treatment window and progression is irreversible, the medical urgency argument for bypassing a delay is particularly strong.

## Federal Appeal Framework

• Step-therapy override request: Submit simultaneously with or before the formal appeal. Cigna's provider portal or clinical team handles these; the prescriber's office typically initiates. Include all documentation supporting the override criteria.
• Internal appeal: File within the deadline on your Explanation of Benefits if the override is denied. Cigna must decide within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719): After an adverse internal decision, request independent external review. For step-therapy disputes, the external reviewer applies clinical standards to determine whether the required step is appropriate for your case. The window is generally up to four months from the denial notice.
• ERISA §503: Employer-plan members have federal full-and-fair review rights.
• State step-therapy laws: Many states have enacted step-therapy override protections; Cigna-insured individuals in those states have additional procedural protections.

## Documentation to Gather

1. Step drug trial history — Dates, doses, duration, and outcomes (inefficacy or adverse effects) for any prior antifibrotic agents. If no prior trial occurred, the prescriber must explain why trial of the step drug is clinically inappropriate. 2. Medical contraindication documentation — If the required step drug is contraindicated for this patient, the prescriber's letter must explain the clinical basis; reference the relevant prescribing label for the step drug, not a numeric threshold. 3. Diagnosis and disease severity — Specialist records confirming IPF and documenting current clinical status, urgency of treatment, and disease course. 4. Prescriber medical-necessity letter — Explicitly addresses why Ofev is the appropriate agent, why the step requirement should be overridden, and references the applicable professional guideline organization (e.g., ATS/ERS/JRS/ALAT). 5. Applicable guideline context — The prescriber may reference the guideline organization's recommendations for IPF management to support the clinical rationale.

## Criteria-Mapping Structure

Obtain Cigna's current step-therapy and antifibrotic coverage policies. For each stated step-therapy override criterion:

• Prior trial of required step drug with dates and outcomes — pharmacy records and chart notes
• Clinical contraindication or inappropriateness of the step drug — prescriber letter with label reference
• Medical necessity and urgency of Ofev for this patient — specialist records
• Alignment with applicable guideline organization recommendations

A step-therapy override packet that pre-addresses every published override criterion — presented in a side-by-side format — is the single most effective tool for achieving a rapid favorable decision.